XBI catalysts
Catalysts and events linked to XBI, newest first.
XBI stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO Congress 2026-10-19 · Up | biotech sentiment uplift on positive late-stage clinical oncology efficacy readouts | Broad small/mid-cap biotech index captures oncology pipeline valuation adjustments. | Not recorded |
| Viking Therapeutics raises $575M via equity and convertible notes 2026-10-19 · Up | clinical biotech balance sheet de-risking | Successful large-scale liquidity event validates capital access for development-stage biotech. | Not recorded |
| Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share 2026-10-06 · Watch | biotechnology primary equity issuance liquidity absorption | Broad biotech ECM activity remains active across clinical stage developers. | Not recorded |
| Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial 2026-10-04 · Watch | biotechnology sentiment transmission from antibody-drug conjugate clinical readouts | Oncology clinical milestones impact broader biotechnology sentiment. | Not recorded |
| ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq 2026-09-25 · Up | biotech primary equity issuance sentiment | Upsized IPO pricing reflects sustained primary market demand for clinical-stage biotech. | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share 2026-09-25 · Up | biotech primary issuance ECM market liquidity validation | Upsized biotech IPO completions demonstrate institutional demand for clinical-stage pipelines. | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 2026-09-25 · Up | biotech equity primary market issuance momentum | Successful large-scale biotech IPO issuance provides sentiment support for the sector. | Not recorded |
| FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA 2026-09-14 · Up | biotech sector risk appetite via high-profile clinical approval | Approval demonstrates regulatory pathway viability for rare disease platform biotechs. | Not recorded |
Do these developments change your position?
Review XBI alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqXBI-0.39%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareADRX XBI-3.04%
- 2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAXBI+0.40%
- 2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMASRRK XBI+0.40%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label → Bullish XBIXBI-3.26%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorXBI-1.79%
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorRVMD XBI-1.79%
- 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsIONS TEVA XBI-2.50%
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorRVMD XBI-1.79%
- 2026-07-24Scribe Therapeutics Prices Upsized $128.7M IPO; Trading Starts TodaySCTX XBI-2.31%
- 2026-07-22Trump announced 100% tariffs on generic drugs with delayed implementationGENERIC DRUG IMPORTERS XBI XPH-2.76%
- 2026-07-17European Commission approves JASCAYD for fibrotic lung diseases across the EUIHE SXDP XBI-2.45%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionXBI-3.40%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionXBI-3.40%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS XBI-3.40%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS XBI-3.40%
- 2026-06-30Big Pharma 'Merger Mania' Driven by $300B Patent CliffLLY XBI+2.98%
- 2026-05-27Eli Lilly expands into vaccines with billion-dollar acquisition waveLLY XBI-3.44%
- 2026-05-21Eli Lilly Obesity Drug Retatrutide Shows 28.3% Weight Loss in Phase 3 TrialLLY NVO XBI+2.81%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.